BiondVax Pharmaceuticals (NASDAQ:BVXV) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) in a report issued on Monday. The firm issued a sell rating on the stock.

Separately, Aegis started coverage on BiondVax Pharmaceuticals in a research note on Wednesday, January 26th. They issued a buy rating and a $7.00 target price for the company.

Shares of NASDAQ:BVXV opened at $1.62 on Monday. The firm has a market capitalization of $18.39 million, a PE ratio of -2.13 and a beta of 2.52. The company has a debt-to-equity ratio of 2.71, a current ratio of 7.64 and a quick ratio of 7.64. The business has a 50-day moving average of $1.41 and a two-hundred day moving average of $1.77. BiondVax Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $4.19.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last posted its earnings results on Monday, March 28th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.18). As a group, research analysts anticipate that BiondVax Pharmaceuticals will post -0.35 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of BVXV. Millennium Management LLC purchased a new position in BiondVax Pharmaceuticals in the second quarter valued at about $33,000. Citadel Advisors LLC bought a new position in BiondVax Pharmaceuticals during the 3rd quarter worth approximately $40,000. TRUE Private Wealth Advisors lifted its holdings in BiondVax Pharmaceuticals by 80.0% during the 3rd quarter. TRUE Private Wealth Advisors now owns 27,000 shares of the company’s stock worth $59,000 after buying an additional 12,000 shares during the last quarter. Envestnet Asset Management Inc. bought a new position in BiondVax Pharmaceuticals during the 4th quarter worth approximately $118,000. Finally, Morgan Stanley lifted its holdings in BiondVax Pharmaceuticals by 24.3% during the 2nd quarter. Morgan Stanley now owns 51,592 shares of the company’s stock worth $148,000 after buying an additional 10,071 shares during the last quarter. 2.68% of the stock is owned by hedge funds and other institutional investors.

About BiondVax Pharmaceuticals (Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Recommended Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.